INBX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -3.91%, SMA50 -1.62%, SMA200 65.22%). The stock’s 14-day RSI is 46.99 (neutral), while the ATR of 5.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.33% below its high and over 614.76% above its low. Average 10-day trading volume of 278.54 thousand shares is in line with the 3-month average of 291.94 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$2.28. The next quarter is forecast at -$2.08. Next year's EPS is expected at $6.22. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $245.00 to $150.00. The high target offers 133.47% upside. The low target suggests 42.94% downside. The mean target is $197.50. This offers 88.2% upside. Inhibrx Biosciences Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 0.0%. The prior quarter beat by 28.36%. Over the last six quarters, Apple has recorded several small beats. These include -36.64% in August 13, 2025.

Inhibrx Biosciences Inc. has 14.49 million shares outstanding. The public float is 7.81 million shares, elevated short interest at 6.45% of float. This equals 676.80 thousand shares. The short ratio is 4.92 days. Institutional investors hold 107.03% of the float. Insiders own 23.16%. Eckelman Living Trust Dated February 5, 2014 holds 2.24 million shares, Eckelman Brendan P. has 1.74 million shares and Lappe Mark has 705.55 thousand shares.

Inhibrx Biosciences Inc. last paid a dividend of 0.85 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.80. This means the shares are trading above this model’s fair value.

Inhibrx Biosciences Inc. (NASDAQ:INBX) closed at $104.94 USD, gaining $1.31 (1.26%) from the previous close of $103.63. The stock is currently mid-range between its 52-week high and low $24.27 and $155.29. With a market capitalization of about $1.54 billion, Inhibrx Biosciences Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.52). Key stats such as the average daily volume over the past year has been around 294.57 thousand shares, in line with its 52-week average. Headquartered in La Jolla, CA, Inhibrx Biosciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mark Lappe, the company employs approximately 110 people and listed since May 29, 2024. Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms.

Inhibrx Biosciences Inc. trades at a P/E ratio of -11.48, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -30.15 indicating negative book value, which may reflect financial stress. The P/FCF stands at -11.34, also below market averages.

Our AI price prediction model suggests that Inhibrx Biosciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.96%, with price expected at $111.19 by September 04, 2026, within a range of $107.44 to $115.21 3-Month Outlook: Projected rise of 29.07%, reaching $135.45 by November 19, 2026, with a range of $133.91 to $136.85. 1-Year Outlook: Projected gain of 24.36%, with price at $130.50 by August 20, 2027, within a range of $120.90 to $137.70.

Inhibrx Biosciences Inc. (NASDAQ:INBX) shares are flat -7.72% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Inhibrx Biosciences Inc. trading at a premium to the broader market with a P/E of -11.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $66.67, suggesting -36.47% downside. Our AI forecast model points to short-term strength (5.96% over two weeks), a medium-term rise (29.07% over three months), and a longer-term gain (24.36% over one year), with expected trading ranges indicating moderate volatility.